Trial Profile
A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary) ; Budesonide; Budesonide/formoterol; Fluticasone propionate; Formoterol; Salmeterol; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Acronyms QvarvsCombo
- 17 Oct 2012 New trial record